Neurofibromatosis type 2 (NF2): a clinical and molecular review

D Gareth R Evans, D Gareth R Evans

Abstract

Neurofibromatosis type 2 (NF2) is a tumour-prone disorder characterised by the development of multiple schwannomas and meningiomas. Prevalence (initially estimated at 1: 200,000) is around 1 in 60,000. Affected individuals inevitably develop schwannomas, typically affecting both vestibular nerves and leading to hearing loss and deafness. The majority of patients present with hearing loss, which is usually unilateral at onset and may be accompanied or preceded by tinnitus. Vestibular schwannomas may also cause dizziness or imbalance as a first symptom. Nausea, vomiting or true vertigo are rare symptoms, except in late-stage disease. The other main tumours are schwannomas of the other cranial, spinal and peripheral nerves; meningiomas both intracranial (including optic nerve meningiomas) and intraspinal, and some low-grade central nervous system malignancies (ependymomas). Ophthalmic features are also prominent and include reduced visual acuity and cataract. About 70% of NF2 patients have skin tumours (intracutaneous plaque-like lesions or more deep-seated subcutaneous nodular tumours). Neurofibromatosis type 2 is a dominantly inherited tumour predisposition syndrome caused by mutations in the NF2 gene on chromosome 22. More than 50% of patients represent new mutations and as many as one-third are mosaic for the underlying disease-causing mutation. Although truncating mutations (nonsense and frameshifts) are the most frequent germline event and cause the most severe disease, single and multiple exon deletions are common. A strategy for detection of the latter is vital for a sensitive analysis. Diagnosis is based on clinical and neuroimaging studies. Presymptomatic genetic testing is an integral part of the management of NF2 families. Prenatal diagnosis and pre-implantation genetic diagnosis is possible. The main differential diagnosis of NF2 is schwannomatosis. NF2 represents a difficult management problem with most patients facing substantial morbidity and reduced life expectancy. Surgery remains the focus of current management although watchful waiting with careful surveillance and occasionally radiation treatment have a role. Prognosis is adversely affected by early age at onset, a higher number of meningiomas and having a truncating mutation. In the future, the development of tailored drug therapies aimed at the genetic level are likely to provide huge improvements for this devastating condition.

References

    1. Evans DGR, Huson S, Donnai D, Neary W, Blair V, Newton V, Harris R. A clinical study of type 2 neurofibromatosis. Q J Med. 1992;84:603–618.
    1. Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C, Hoang-xuan K, Demczuk S, Desmaze C, Plougastel B, Pulst SM, Lenoir G, Bijlsma E, Fashold R, Dumanski J, de Jong P, Parry D, Eldridge R, Aurias A, Delattre O, Thomas G. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature. 1993;363:515–521. doi: 10.1038/363515a0.
    1. Troffater JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Eldridge R, Kley N, Menon AG, Pulaski K, Haase VH, Ambrose CM, Munroe D, Bove C, Haines JL, Martuza RL, MacDonald ME, Seizinger BR, Short PM, Buckler AJ, Gusella JF. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell. 1993;72:791–800. doi: 10.1016/0092-8674(93)90406-G.
    1. Evans DGR, Wallace A, Trueman L, Strachan T. Mosaicism in classical neurofibromatosis type 2: a common mechanism for sporadic disease in tumor prone syndromes? Am J Hum Genet. 1998;63:727–736.
    1. Evans DGR, Huson SM, Donnai D, Neary W, Blair V, Teare D, Ramsden RT, Harris R. A genetic study of type 2 neurofibromatosis in the north west of England and the UK: I. Prevalence, mutation rate, fitness and confirmation of maternal transmission effect on severity. J Med Genet. 1992;29:841–846. doi: 10.1136/jmg.29.12.841.
    1. Evans DGR, Moran A, King A, Saeed S, Gurusinghe N, Ramsden R. Incidence of Vestibular Schwannoma and Neurofibromatosis 2 in the North West of England over a 10 year period: higher incidence than previously thought. Otol Neurotol. 2005;26:93–97. doi: 10.1097/00129492-200501000-00016.
    1. Antinheimo J, Sankila R, Carpén O, Pukkala E, Sainio M, Jääskeläinen J. Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas. Neurology. 2000;54:71–76.
    1. Wishart JH. Case of tumours in the skull, dura mater, and brain. Edinburgh Med Surg J. 1822;18:393–397.
    1. Cushing H. Tumors of the nervus acusticus and the syndrome of the cerebello-pontine angle. WB Saunders, Philadelphia, USA; 1917.
    1. Crowe FW, Schull WJ, Neal JV. A clinical pathological and genetic study of multiple neurofibromatosis. Springfield, Illinois, USA: Charles C. Thomas; 1956.
    1. Kanter WR, Eldridge R, Fabricant R, Allen JC, Koerber T. Central neurofibromatosis with bilateral acoustic neuroma. Genetic, clinical and biochemical distinctions from peripheral neurofibromatosis. Neurol. 1980;30:851–859.
    1. Parry DM, Eldridge R, Kaiser-Kupfer MI, Bouzas EA, Pikus A, Patronas N. Neurofibromatosis 2 (NF2): Clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet. 1994;52:450–451. doi: 10.1002/ajmg.1320520411.
    1. Mautner VF, Lindenau M, Baser ME, Hazim W, Tatagiba M, Haase W, Samii M, Wais R, Pulst SM. The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurg. 1996;38:880–885. doi: 10.1097/00006123-199605000-00004.
    1. Evans DGR, Ramsden R, Birch J. Paediatric presentation of type 2 neurofibromatosis. Arch Dis Child. 1999;81:496–499. doi: 10.1136/adc.81.6.496.
    1. Sperfeld AD, Hein C, Schroder JM, Ludolph AC, Hanemann CO. Occurrence and characterization of peripheral nerve involvement in neurofibromatosis type 2. Brain. 2002;125:996–1004. doi: 10.1093/brain/awf115.
    1. Seizinger BR, Rouleau GA, Ozelius LG, Ozelius LJ, Faryniarz AG, Iannazzi J, Hobbs W, Roy JC, Falcone B, Huson S. Genetic linkage of von Recklinghausen neurofibromatosis to the nerve growth factor receptor gene. Cell. 1987;49:589–594. doi: 10.1016/0092-8674(87)90534-4.
    1. Rouleau G, Seizinger BR, Ozelius LG, Hobbs WJ, Trofatter JA, Seizinger BR, Martuza RL, Superneau DW, Conneally PM, Gusella JF. Genetic linkage analysis of bilateral acoustic neurofibromatosis to a DNA marker on chromosome 22. Nature. 1987;329:246–248. doi: 10.1038/329246a0.
    1. National Institutes of Health Consensus Development Conference Statement on Neurofibromatosis Arch Neurol . 1987. pp. 575–578.
    1. Seizinger BR, Martuza RL, Gusella JF. Loss of genes on chromosome 22 in tumorigenesis of human acoustic neuroma. Nature. 1986;322:644–647. doi: 10.1038/322644a0.
    1. MacCollin M, Ramesh V, Jacoby LB, Louis DN, Rubio MP, Pulaski K, Trofatter JA, Short MP, Bove C, Eldridge R. Mutationalanalysis of patients with neurofibromatosis 2. Am J Hum Genet. 1994;55:314–320.
    1. Parry DM, MacCollin M, Kaiser-Kupfer MI, Pulaski K, Nicholson HS, Boleseta M, Eldridge R, Gusella JF. Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. Am J Hum Genet. 1996;59:529–539.
    1. Ruttledge MH, Andermann AA, Phelan CM, Claudio JO, Han F-y, Chretien N, Rangaratnam S, MacCollin M, Short P, Parry D, Michels V, Riccardi VM, Weksberg R, Kitamura K, Bradburn JM, Hall BD, Propping P, Rouleau GA. Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. Am J Hum Genet. 1996;59:331–342.
    1. Kluwe L, Bayer S, Baser ME, Hazim W, Haase W, Funsterer C, Mautner VF. Identification of NF2 germ-line mutations and comparison with neurofibromatosis 2 phenotypes. [published erratum in Hum Genet 1997;99(2):292] Hum Genet. 1996;98:534–538. doi: 10.1007/s004390050255.
    1. Kluwe L, MacCollin M, Tatagiba M, Thomas S, Hazim W, Haase W, Mautner VF. Phenotypic variability associated with 14 splice-site mutations in the NF2 gene. Am J Med Genet. 1998;77:228–233. doi: 10.1002/(SICI)1096-8628(19980518)77:3<228::AID-AJMG8>;2-L.
    1. Evans DGR, Trueman L, Wallace A, Mason S, Strachan T. Genotype/phenotype correlations in type 2 neurofibromatosis: evidence for more severe disease with truncating mutations. J Med Genet. 1998;35:450–455. doi: 10.1136/jmg.35.6.450.
    1. Baser ME, Kuramoto L, Joe H, Kuramoto L, Joe H, Friedman JM, Wallace AJ, Ramsden RT, Evans DG. Genotype-Phenotype Correlations for Nervous System Tumors in Neurofibromatosis 2: A Population-Based Study. Am J Hum Genet. 2004;75:231–239. doi: 10.1086/422700.
    1. Baser ME, Kuramoto L, Woods RH, Friedman JM, Wallace AJ, Ramsden RT, Olschwang S, Bijlsma E, Kalamarides M, Papi L, Kato L, Evans DG. The location of constitutional neurofibromatosis 2 (NF2) splice-site mutations is associated with the severity of NF2. J Med Genet. 2005;42:540–6. doi: 10.1136/jmg.2004.029504.
    1. Tsilchorozidou T, Menko F, Lalloo F, Kidd A, Da Silva R, Smith P, Malcolmson A, Dore J, Madan K, Brown A, Yovos JG, Tsaligopoulos M, Vogiatzis N, Wallace A, Evans DGR. Constitutional rearrangements of chromosome 22 as a cause of neurofibromatosis type 2. J Med Genet. 2004;41:529–534. doi: 10.1136/jmg.2003.016774.
    1. Kluwe L, Nygren AO, Errami A, Heinrich B, Matthies C, Tatagiba M, Mautner V. Screening for large mutations of the NF2 gene. Genes Chromosomes Cancer. 2005;42:384–391. doi: 10.1002/gcc.20138.
    1. Baser ME. Neurofibromatosis 2 (NF2) mutation databases
    1. Baser ME, the contributors to the International NF2 Database Mutation The distribution of constitutional and somatic mutations in the neurofibromatosis 2 gene. Hum Mutat . 2006;27:297–306. doi: 10.1002/humu.20317.
    1. Ahronowitz I, Xin W, Kiely R, Sims K, Maccollin M, Nunes FP. Mutational spectrum of the NF2 gene: a meta-analysis of 12 years of research and diagnostic laboratory findings. Hum Mutat. 2007;28:1–12. doi: 10.1002/humu.20393.
    1. Kluwe L, Mautner VF, Heinrich B, Dezube R, Jacoby LB, Friedrich RE, MacCollin M. Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas. J Med Genet. 2003;40:109–114. doi: 10.1136/jmg.40.2.109.
    1. Moyhuddin A, Baser ME, Watson C, Purcell S, Ramsden RT, Heiberg A, Wallace AJ, Evans DGR. Somatic mosaicism in neurofibromatosis 2:prevalence and risk of disease transmission to offspring. J Med Genet. 2003;40:459–463. doi: 10.1136/jmg.40.6.459.
    1. Evans DG, Ramsden RT, Shenton A, Gokhale C, Bowers NL, Huson SM, Wallace A. Mosaicism in NF2 an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including MLPA. J Med Genet. 2007;44:424–428. doi: 10.1136/jmg.2006.047753.
    1. Evans DGR, Maher ER, Baser ME. Age-related shift in the mutation spectra of germline and somatic NF2 mutations: hypothetical role of DNA repair mechanisms. J Med Genet. 2005;42:630–632. doi: 10.1136/jmg.2004.027953.
    1. Warren C, James LA, Varley JM, Ramsden RT, Evans DG. Identifying Recurrent Regions of Chromosome Loss and Gain in 76 Vestibular Schwannomas Using Comparative Genomic Hybridisation (CGH) J Med Genet. 2003;40:802–806. doi: 10.1136/jmg.40.11.802.
    1. Kino T, Takeshima H, Nakao M, Nishi T, Yamamoto K, Kimura T, Saito Y, Kochi M, Kuratsu J-i, Saya H, Ushio Y. Identification of the cis-acting region in the NF2 gene promoter as a potential target for mutation and methylation-dependent silencing in schwannoma. Genes Cells. 2001;6:441–454. doi: 10.1046/j.1365-2443.2001.00432.x.
    1. Gonzalez-Gomez P, Bello MJ, Alonso ME, Lomas J, Lopez-Marin I, Arjona D, de Campos JM, Vaquero J, Isla A, Lassaletta L, Gutierrez M, Sarasa JL, Rey JA. CpG island methylation in sporadic and neurofibromatosis type 2-associated schwannomas. Clin Cancer Res. 2003;9:5601–5606.
    1. Lomas J, Bello MJ, Arjona D, Alonso ME, Martinez-Glez V, Lopez-Marin I, Aminoso C, de Campos JM, Isla A, Vaquero J, Rey JA. Genetic and epigenetic alteration of the NF2 gene in sporadic meningiomas. Genes Chrom Cancer. 2005;42:314–319. doi: 10.1002/gcc.20141.
    1. Evans DGR, Ramsden RT, Shenton A, Gokhale C, Bowers NL, Huson SM, Wallace A. What are the implications in individuals with unilateral vestibular schwannoma and other neurogenic tumors? J Neurosurg. 2008;108:92–96. doi: 10.3171/JNS/2008/108/01/0092.
    1. Evans DGR, Ramsden RT, Shenton A, Gokhale C, Bowers NL, Huson SM, Wallace A. Should NF2 mutation screening be undertaken in patients with an apparently isolated vestibular schwannoma? Clin Genet. 2007;71:354–358. doi: 10.1111/j.1399-0004.2007.00778.x.
    1. Baser ME, Friedman JM, Wallace AJ, Ramsden RT, Joe H, Evans DG. Evaluation of diagnostic criteria for neurofibromatosis 2. Neurology. 2002;59:1759–1765. doi: 10.1001/archneur.59.11.1759.
    1. Evans DGR, Newton V, Neary W, Baser ME, Wallace A, MacLeod R, Jenkins JPR, Gillespie J, Ramsden R. Use of MRI and audiological tests in pre-symptomatic diagnosis of type 2 neurofibromatosis (NF2) J Med Genet. 2000;37:944–947. doi: 10.1136/jmg.37.12.944.
    1. Mohyuddin A, Neary WJ, Wallace AJ, Purcell S, Wu C-L, Reid H, Ramsden RT, Read AP, Evans DGR. Molecular genetic exclusion of NF2 in young patients diagnosed with a unilateral vestibular schwannoma. J Med Genet. 2002;39:315–322. doi: 10.1136/jmg.39.5.315.
    1. Kluwe L, Freidrich RE, Tatagiba M, Mautner V. Presymptomatic diagnosis for children of sporadic neurofibromatosis 2 patients, a method based on tumor analysis. Genet Med. 2002;4:27–30.
    1. Mautner VF, Lindenau M, Baser ME, Tatagiba M, Haase W, Samii M, Wais R, Pulst SM. The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurg. 1996;38:880–885. doi: 10.1097/00006123-199605000-00004.
    1. King A, Biggs N, Ramsden RT, Wallace A, Gillespie J, Evans DGR. Spinal tumors in neurofibromatosis type 2: is emerging knowledge of genotype predictive of natural history? J Neurosurg Spine. 2005;2:574–579. doi: 10.3171/spi.2005.2.5.0526.
    1. Patronas NJ, Courcoutsakis N, Bromley CM, Katzman GL, MacCollin M, Parry DM. Intramedullary and spinal canal tumors in patients with neurofibromatosis 2: MR imaging findings and correlation with genotype. Radiology. 2001;218:434–442.
    1. Evans DGR, Ramsden R, Huson SM, Harris R, Lye R, King TT. Type 2 neurofibromatosis: the need for supraregional care? J Laryngol Otol. 1993;107:401–406.
    1. Slattery WH, Brackmann DE, Hitselberger W. Hearing preservation in neurofibromatosis type 2. Am J Otol. 1998;19:638–643.
    1. Evans DGR, Baser ME, O'Reilly B, Rowe J, Gleeson M, Saeed S, King A, Huson S, Kerr R, Thomas N, Irving R, MacFarlane R, Ferner R, McLeod R, Moffat D, Ramsden R. Management of the patient and family with Neurofibromatosis 2: A consensus conference statement. Brit J Neurosurg. 2005;19:5–12. doi: 10.1080/02688690500081206.
    1. Baser ME, Friedman JM, Aeschilman D, Joe H, Wallace AJ, Ramsden RT, Evans DGR. Predictors of the risk of mortality in neurofibromatosis 2. Am J Hum Genet. 2002;71:715–723. doi: 10.1086/342716.
    1. Sobel RA, Wang Y. Vestibular (acoustic) schwannomas: histological features in neurofibromatosis 2 and in unilateral cases. J Neuropathol Exp Neurol. 1993;52:106–113. doi: 10.1097/00005072-199303000-00002.
    1. Rowe JG, Radatz M, Walton L, Kemeny AA. Stereotactic radiosurgery for type 2 neurofibromatosis acoustic neuromas: patient selection and tumour size. Stereotact Funct Neurosurg. 2002;79:107–116. doi: 10.1159/000070106.
    1. Rowe JG, Radatz MW, Walton L, Soanes T, Rodgers J, Kemeny AA. Clinical experience with gamma knife stereotactic radiosurgery in the management of vestibular schwannomas secondary to type 2 neurofibromatosis. J Neurol Neurosurg Psychiatry. 2003;74:1288–1293. doi: 10.1136/jnnp.74.9.1288.
    1. Baser ME, Evans DGR, Jackler RK, Sujansky E, Rubenstein A. Malignant peripheral nerve sheath tumors, radiotherapy, and neurofibromatosis 2. Brit J Cancer. 2000;82:998. doi: 10.1054/bjoc.1999.1030.
    1. Evans DGR, Birch JM, Ramsden RT, Sharif S, Baser ME. Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour-prone syndromes. J Med Genet. 2006;43:289–94. doi: 10.1136/jmg.2005.036319.
    1. Friedmann RA, Slattery WH, Brackmann DE, Shwartz MS, Hitselberger WE. Resection of Acoustic Neuroma following Failed Stereotactic Radiosurgical Treatment: Facial nerve outcome. In: Baguley DM, Ramsden RT, Moffat DA, editor. Fourth International Conference on Vestibular Schwannoma and Other CPA Lesions Conference Proceedings. Pubs: Immediate Proceedings, Bungay, Norfolk, UK; pp. 29–30.
    1. Evans DG, Kalamarides M, Hunter-Schaedle K, et al. Consensus Recommendations to Accelerate Clinical Trials for Neurofibromatosis Type 2. Clin Cancer Res. 2009.
    1. Hanemann CO. Magic but treatable? Tumours due to loss of merlin. Brain. 2008;131:606–615. doi: 10.1093/brain/awm249.
    1. Plotkin SR, Singh MA, O'Donnell CC, Harris GJ, McClatchey AI, Halpin C. Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy. Nat Clin Pract Oncol. 2008;5:487–491. doi: 10.1038/ncponc1157.
    1. Ammoun S, Flaiz C, Ristic N, Schuldt J, Hanemann CO. Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma. Cancer Res. 2008;68:5236–5245. doi: 10.1158/0008-5472.CAN-07-5849.
    1. Evans DGR, Huson SM, Donnai D, Neary W, Blair V, Newton V, Strachan T, Harris R. A genetic study of type 2 neurofibromatosis: II Guidelines for genetic counselling. J Med Genet . 1992;29:846–852.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe